Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles

Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. To measure antibodies of IgG isoty...

Full description

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 136; no. 1; pp. 161 - 163
Main Authors Pengo, V., Ruffatti, A., Tonello, M., Hoxha, A., Bison, E., Denas, G., Padayattil Jose, S., Zoppellaro, G., Bracco, A., Banzato, A.
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.07.2015
Subjects
Online AccessGet full text
ISSN0049-3848
1879-2472
1879-2472
DOI10.1016/j.thromres.2015.04.031

Cover

Abstract Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. Patients/Methods. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10). Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism. Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events. •aβ2GP1 is a lab criterion in antiphospholipid syndrome•aβ2GP1 comprises antibodies directed to different domains of the molecule•Higher values of IgG aβ2GP1-Dm4/5 in patients with sole positivity for IgG aβ2GP1•No association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events
AbstractList Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. Patients/Methods. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10). Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism. Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events. •aβ2GP1 is a lab criterion in antiphospholipid syndrome•aβ2GP1 comprises antibodies directed to different domains of the molecule•Higher values of IgG aβ2GP1-Dm4/5 in patients with sole positivity for IgG aβ2GP1•No association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events
Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories.BACKGROUNDDetermination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories.To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1.OBJECTIVESTo measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1.In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10).PATIENTS/METHODSIn this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10).Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism.RESULTSGeometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism.Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.CONCLUSIONMean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.
Abstract Background Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. Objectives To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. Patients/Methods. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC +, IgG aCL +, IgG aβ2GP1 +, n = 32), double (LAC-, IgG aCL +, IgG aβ2GP1 +, n = 23) or single positive (LA-, IgG aCL-, IgG aβ2GP1 +, n = 10). Results Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795 ± 783, 321 ± 181, 29 ± 8 and 5.0 ± 1.0, respectively (ANOVA p < 0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16 ± 0.13, 0.16 ± 0.15 and 0.26 ± 0.15, 0.13 ± 0,11, respectively (ANOVA p < 0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p = 0.04) and double (p = 0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism. Conclusion Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.
Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10). Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism. Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.
Author Bison, E.
Banzato, A.
Zoppellaro, G.
Pengo, V.
Padayattil Jose, S.
Denas, G.
Ruffatti, A.
Hoxha, A.
Tonello, M.
Bracco, A.
Author_xml – sequence: 1
  givenname: V.
  surname: Pengo
  fullname: Pengo, V.
  email: vittorio.pengo@unipd.it
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 2
  givenname: A.
  surname: Ruffatti
  fullname: Ruffatti, A.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 3
  givenname: M.
  surname: Tonello
  fullname: Tonello, M.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 4
  givenname: A.
  surname: Hoxha
  fullname: Hoxha, A.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 5
  givenname: E.
  surname: Bison
  fullname: Bison, E.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 6
  givenname: G.
  surname: Denas
  fullname: Denas, G.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 7
  givenname: S.
  surname: Padayattil Jose
  fullname: Padayattil Jose, S.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 8
  givenname: G.
  surname: Zoppellaro
  fullname: Zoppellaro, G.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 9
  givenname: A.
  surname: Bracco
  fullname: Bracco, A.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
– sequence: 10
  givenname: A.
  surname: Banzato
  fullname: Banzato, A.
  organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25959581$$D View this record in MEDLINE/PubMed
BookMark eNqNUsFqGzEQFSWlcdL-QtDRPqwzWmm9KyilIUndgqGBtmehlWaJ3N2VK8kB_1Y_pN8UuY4vOTRlECON3nsj9OaMnIx-REIuGMwZsMXlep7ugx8CxnkJrJqDmANnr8iENbUsSlGXJ2QCIGTBG9GckrMY1wCsZrJ6Q07LSuZo2IRsr8bkWm8dRpo8vfGDdiMVlxWd3gw5zajv6J_fZbHsd8Zvgk-Y7xmd5tryjs1oPlnXdRhwTFRnsc29j3n1buMsneq71exvOffY0czvXI_xLXnd6T7iu6d8Tn58uv1-_blYfV1-ub5aFUYseCqYEFp2tQZpcnRowKJprDSGi6bt2rpsS64l6IbnTdvyiuvW1rWF1lZCLvg5mR50c-NfW4xJDS4a7Hs9ot9GxRaN5CChKjP04gm6bQe0ahPcoMNOHb8qA94fACb4GAN2yrikk_NjCtr1ioHaO6PW6uiM2jujQKjsTKYvntGPHV4kfjwQMX_Ug8OgonE4GrQuoEnKeveyxIdnEqZ3ozO6_4k7jGu_DWO2QTEVSwXq235u9mPDKoASOPxb4H9e8AgFx9bn
CitedBy_id crossref_primary_10_1111_aji_13258
crossref_primary_10_1016_j_ejim_2020_07_020
crossref_primary_10_1016_j_thromres_2019_11_029
crossref_primary_10_1024_0301_1526_a000723
crossref_primary_10_1016_j_reumae_2018_11_012
crossref_primary_10_1177_0961203317692432
crossref_primary_10_1007_s11926_018_0772_y
crossref_primary_10_1186_s12948_016_0043_2
crossref_primary_10_1055_s_0042_1749590
crossref_primary_10_1016_j_autrev_2017_09_003
crossref_primary_10_1186_s12916_017_0807_7
crossref_primary_10_1177_0961203316641772
crossref_primary_10_1038_srep23839
crossref_primary_10_1111_jth_13976
crossref_primary_10_1586_1744666X_2015_1080121
crossref_primary_10_1016_j_autrev_2018_08_003
crossref_primary_10_1016_j_autrev_2018_06_011
crossref_primary_10_1016_S1773_035X_20_30096_4
crossref_primary_10_1111_jth_14682
crossref_primary_10_1586_17474086_2016_1140034
crossref_primary_10_1093_rheumatology_kead675
crossref_primary_10_1186_s13075_016_1018_x
crossref_primary_10_1016_j_ejim_2022_10_010
crossref_primary_10_1093_rheumatology_kead632
crossref_primary_10_1111_aji_12792
crossref_primary_10_1016_j_jaut_2018_02_002
crossref_primary_10_1016_j_autrev_2016_07_028
crossref_primary_10_1016_j_cca_2018_06_037
crossref_primary_10_1177_09612033231211820
crossref_primary_10_1111_jth_14896
crossref_primary_10_1111_ijlh_12507
crossref_primary_10_1016_j_reuma_2018_11_003
crossref_primary_10_1016_j_autrev_2018_03_018
crossref_primary_10_1016_j_ejim_2023_01_012
crossref_primary_10_1016_j_thromres_2018_07_011
Cites_doi 10.1055/s-0037-1614453
10.1111/j.1365-2796.2011.02362.x
10.1111/jth.12537
10.1182/blood-2004-09-3387
10.1182/blood-2013-11-537704
10.1136/ard.2010.137281
10.1111/jth.12264
10.1182/blood-2002-02-0441
10.1016/j.jaut.2006.09.007
10.1111/j.1538-7836.2009.03674.x
10.1111/j.1538-7836.2009.03555.x
10.1111/j.1538-7836.2009.03588.x
10.1111/j.1538-7836.2006.01753.x
10.1093/intimm/dxf043
10.1177/0961203310395055
10.1055/s-0037-1613055
10.1016/j.thromres.2011.04.021
10.1111/jth.12865
ContentType Journal Article
Copyright 2015 Elsevier Ltd
Elsevier Ltd
Copyright © 2015 Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2015 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2015 Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.thromres.2015.04.031
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-2472
EndPage 163
ExternalDocumentID 25959581
10_1016_j_thromres_2015_04_031
S0049384815002030
1_s2_0_S0049384815002030
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29Q
3O-
4.4
457
4CK
4G.
53G
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEB
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OC~
OO-
OZT
P-8
P-9
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
WUQ
X7M
Z5R
ZGI
~G-
0SF
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
NCXOZ
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
EFLBG
LCYCR
ZA5
AAYXX
ACLOT
CITATION
~HD
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c463t-144a9f7a09c9c9fec0dec8d9cc348bfb72b23a90a83b23bb353abd77d0bd54963
IEDL.DBID .~1
ISSN 0049-3848
1879-2472
IngestDate Sun Sep 28 11:20:14 EDT 2025
Thu Apr 03 07:10:31 EDT 2025
Wed Oct 01 03:08:59 EDT 2025
Thu Apr 24 23:06:41 EDT 2025
Fri Feb 23 02:34:53 EST 2024
Sun Feb 23 10:19:19 EST 2025
Tue Aug 26 16:32:27 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Antibodies
Glycoproteins
Epitopes
Thrombosis
Antiphospholipid syndrome
Language English
License Copyright © 2015 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c463t-144a9f7a09c9c9fec0dec8d9cc348bfb72b23a90a83b23bb353abd77d0bd54963
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25959581
PQID 1689309052
PQPubID 23479
PageCount 3
ParticipantIDs proquest_miscellaneous_1689309052
pubmed_primary_25959581
crossref_citationtrail_10_1016_j_thromres_2015_04_031
crossref_primary_10_1016_j_thromres_2015_04_031
elsevier_sciencedirect_doi_10_1016_j_thromres_2015_04_031
elsevier_clinicalkeyesjournals_1_s2_0_S0049384815002030
elsevier_clinicalkey_doi_10_1016_j_thromres_2015_04_031
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-07-01
PublicationDateYYYYMMDD 2015-07-01
PublicationDate_xml – month: 07
  year: 2015
  text: 2015-07-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Thrombosis research
PublicationTitleAlternate Thromb Res
PublicationYear 2015
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Galli, Luciani, Bertolini, Barbui (bb0015) 2003; 101
Tripodi, de Groot, Pengo (bb0025) 2011; 270
Pengo, Ruffatti, Tonello, Cuffaro, Banzato, Bison (bb0060) Feb 2 2015
Ambrozic, Avicin, Ichikawa, Kveder, Matsuura, Hojnik (bb0085) 2002; 14
Arvieux, Renaudineau, Mane, Perraut, Krilis, Youinou (bb0080) 2002; 87
Pengo, Biasiolo, Rampazzo, Brocco (bb0020) 1999; 81
Andreoli, Nalli, Motta, Norman, Shums, Encabo (bb0070) 2011; 70
Banzato, Pozzi, Frasson, De Filippis, Ruffatti, Bison (bb0055) 2011; 128
de Laat, Derksen, Urbanus, de Groot (bb0030) 2005; 105
Pengo, Tripodi, Reber, Rand, Ortel, Galli (bb0050) 2009; 7
Iverson, von Muhlen, Staub, Lassen, Binder, Norman (bb0075) 2006; 27
Pengo, Ruffatti, Legnani, Gresele, Barcellona, Erba (bb0010) 2010; 8
Pierangeli, de Groot, Dlott, Favaloro, Harris, Lakos (bb0040) 2011; 20
de Laat, Pengo, Pabinger, Musial, Voskuyl, Bultink (bb0035) 2009; 7
Miyakis, Lockshin, Atsumi, Branch, Brey, Cervera (bb0005) 2006; 4
Pengo, Ruffatti, Del Ross, Tonello, Cuffaro, Hoxha (bb0090) 2013; 11
Devreese, Pierangeli, de Laat, Tripodi, Atsumi, Ortel (bb0045) May 2014; 12
Agostinis, Durigutto, Sblattero, Borghi, Grossi, Guida (bb0065) 2014; 123
Pengo (10.1016/j.thromres.2015.04.031_bb0020) 1999; 81
de Laat (10.1016/j.thromres.2015.04.031_bb0030) 2005; 105
Andreoli (10.1016/j.thromres.2015.04.031_bb0070) 2011; 70
Arvieux (10.1016/j.thromres.2015.04.031_bb0080) 2002; 87
Pengo (10.1016/j.thromres.2015.04.031_bb0010) 2010; 8
Pengo (10.1016/j.thromres.2015.04.031_bb0050) 2009; 7
Miyakis (10.1016/j.thromres.2015.04.031_bb0005) 2006; 4
Devreese (10.1016/j.thromres.2015.04.031_bb0045) 2014; 12
Agostinis (10.1016/j.thromres.2015.04.031_bb0065) 2014; 123
Pengo (10.1016/j.thromres.2015.04.031_bb0060) 2015
Pengo (10.1016/j.thromres.2015.04.031_bb0090) 2013; 11
Galli (10.1016/j.thromres.2015.04.031_bb0015) 2003; 101
Banzato (10.1016/j.thromres.2015.04.031_bb0055) 2011; 128
de Laat (10.1016/j.thromres.2015.04.031_bb0035) 2009; 7
Iverson (10.1016/j.thromres.2015.04.031_bb0075) 2006; 27
Tripodi (10.1016/j.thromres.2015.04.031_bb0025) 2011; 270
Pierangeli (10.1016/j.thromres.2015.04.031_bb0040) 2011; 20
Ambrozic (10.1016/j.thromres.2015.04.031_bb0085) 2002; 14
References_xml – volume: 87
  start-page: 599
  year: 2002
  end-page: 605
  ident: bb0080
  article-title: Distinguishing features of anti-beta2glycoprotein Iantibodies between patients with leprosy and the antiphospholipid syndrome
  publication-title: Thromb Haemost
– volume: 7
  start-page: 1767
  year: 2009
  end-page: 1773
  ident: bb0035
  article-title: The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
  publication-title: J Thromb Haemost
– volume: 81
  start-page: 256
  year: 1999
  end-page: 258
  ident: bb0020
  article-title: dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies
  publication-title: Thromb Haemost
– volume: 20
  start-page: 182
  year: 2011
  end-page: 908
  ident: bb0040
  article-title: ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010
  publication-title: Lupus
– volume: 270
  start-page: 110
  year: 2011
  end-page: 122
  ident: bb0025
  article-title: Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment
  publication-title: J Intern Med
– year: Feb 2 2015
  ident: bb0060
  article-title: Antibodies to Domain 1 (Dm1) of β2-Glycoprotein 1 (β2GP1) correctly classify patients at risk in Antiphospholipid Syndrome (APS)
  publication-title: J Thromb Haemost
– volume: 123
  start-page: 3478
  year: 2014
  end-page: 3487
  ident: bb0065
  article-title: A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome
  publication-title: Blood
– volume: 14
  start-page: 823
  year: 2002
  end-page: 830
  ident: bb0085
  article-title: Antibeta(2)-glycoprotein I antibodies in children with atopic dermatitis
  publication-title: Int Immunol
– volume: 105
  start-page: 1540
  year: 2005
  end-page: 1545
  ident: bb0030
  article-title: IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis
  publication-title: Blood
– volume: 128
  start-page: 583
  year: 2011
  end-page: 586
  ident: bb0055
  article-title: Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)
  publication-title: Thromb Res
– volume: 101
  start-page: 1827
  year: 2003
  end-page: 1832
  ident: bb0015
  article-title: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
  publication-title: Blood
– volume: 12
  start-page: 792
  year: May 2014
  end-page: 795
  ident: bb0045
  article-title: Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH
  publication-title: J Thromb Haemost
– volume: 11
  start-page: 1
  year: 2013
  end-page: 5
  ident: bb0090
  article-title: Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
  publication-title: J Thromb Haemost
– volume: 70
  start-page: 380
  year: 2011
  end-page: 383
  ident: bb0070
  article-title: Anti-β2glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain4/5: might it be the reason for their innocent’ profile?
  publication-title: Ann Rheum Dis
– volume: 8
  start-page: 237
  year: 2010
  end-page: 242
  ident: bb0010
  article-title: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
  publication-title: J Thromb Haemost
– volume: 27
  start-page: 266
  year: 2006
  end-page: 271
  ident: bb0075
  article-title: Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain4 of beta2-GPI
  publication-title: J Autoimmun
– volume: 7
  start-page: 1737
  year: 2009
  end-page: 1740
  ident: bb0050
  article-title: Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
  publication-title: J Thromb Haemost
– volume: 4
  start-page: 295
  year: 2006
  end-page: 306
  ident: bb0005
  article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
  publication-title: J Thromb Haemost
– volume: 81
  start-page: 256
  year: 1999
  ident: 10.1016/j.thromres.2015.04.031_bb0020
  article-title: dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1614453
– volume: 270
  start-page: 110
  issue: 2
  year: 2011
  ident: 10.1016/j.thromres.2015.04.031_bb0025
  article-title: Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2011.02362.x
– volume: 12
  start-page: 792
  issue: 5
  year: 2014
  ident: 10.1016/j.thromres.2015.04.031_bb0045
  article-title: Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12537
– volume: 105
  start-page: 1540
  year: 2005
  ident: 10.1016/j.thromres.2015.04.031_bb0030
  article-title: IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis
  publication-title: Blood
  doi: 10.1182/blood-2004-09-3387
– volume: 123
  start-page: 3478
  year: 2014
  ident: 10.1016/j.thromres.2015.04.031_bb0065
  article-title: A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome
  publication-title: Blood
  doi: 10.1182/blood-2013-11-537704
– volume: 70
  start-page: 380
  year: 2011
  ident: 10.1016/j.thromres.2015.04.031_bb0070
  article-title: Anti-β2glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain4/5: might it be the reason for their innocent’ profile?
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.137281
– volume: 11
  start-page: 1
  year: 2013
  ident: 10.1016/j.thromres.2015.04.031_bb0090
  article-title: Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12264
– volume: 101
  start-page: 1827
  year: 2003
  ident: 10.1016/j.thromres.2015.04.031_bb0015
  article-title: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
  publication-title: Blood
  doi: 10.1182/blood-2002-02-0441
– volume: 27
  start-page: 266
  year: 2006
  ident: 10.1016/j.thromres.2015.04.031_bb0075
  article-title: Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain4 of beta2-GPI
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2006.09.007
– volume: 8
  start-page: 237
  year: 2010
  ident: 10.1016/j.thromres.2015.04.031_bb0010
  article-title: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2009.03674.x
– volume: 7
  start-page: 1737
  year: 2009
  ident: 10.1016/j.thromres.2015.04.031_bb0050
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2009.03555.x
– volume: 7
  start-page: 1767
  year: 2009
  ident: 10.1016/j.thromres.2015.04.031_bb0035
  article-title: The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2009.03588.x
– volume: 4
  start-page: 295
  year: 2006
  ident: 10.1016/j.thromres.2015.04.031_bb0005
  article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2006.01753.x
– volume: 14
  start-page: 823
  year: 2002
  ident: 10.1016/j.thromres.2015.04.031_bb0085
  article-title: Antibeta(2)-glycoprotein I antibodies in children with atopic dermatitis
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxf043
– volume: 20
  start-page: 182
  year: 2011
  ident: 10.1016/j.thromres.2015.04.031_bb0040
  article-title: ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010
  publication-title: Lupus
  doi: 10.1177/0961203310395055
– volume: 87
  start-page: 599
  year: 2002
  ident: 10.1016/j.thromres.2015.04.031_bb0080
  article-title: Distinguishing features of anti-beta2glycoprotein Iantibodies between patients with leprosy and the antiphospholipid syndrome
  publication-title: Thromb Haemost
  doi: 10.1055/s-0037-1613055
– volume: 128
  start-page: 583
  year: 2011
  ident: 10.1016/j.thromres.2015.04.031_bb0055
  article-title: Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2011.04.021
– year: 2015
  ident: 10.1016/j.thromres.2015.04.031_bb0060
  article-title: Antibodies to Domain 1 (Dm1) of β2-Glycoprotein 1 (β2GP1) correctly classify patients at risk in Antiphospholipid Syndrome (APS)
  publication-title: J Thromb Haemost
  doi: 10.1111/jth.12865
SSID ssj0017195
Score 2.295981
Snippet Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti...
Abstract Background Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 161
SubjectTerms Antibodies
Antibodies, Antiphospholipid - blood
Antibodies, Antiphospholipid - immunology
Antiphospholipid syndrome
Antiphospholipid Syndrome - blood
Antiphospholipid Syndrome - immunology
beta 2-Glycoprotein I - chemistry
beta 2-Glycoprotein I - immunology
Cross-Sectional Studies
Epitopes
Epitopes - chemistry
Epitopes - immunology
Glycoproteins
Hematology, Oncology and Palliative Medicine
Humans
Immunoglobulin G - blood
Immunoglobulin G - immunology
Protein Structure, Tertiary
Thrombosis
Title Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0049384815002030
https://www.clinicalkey.es/playcontent/1-s2.0-S0049384815002030
https://dx.doi.org/10.1016/j.thromres.2015.04.031
https://www.ncbi.nlm.nih.gov/pubmed/25959581
https://www.proquest.com/docview/1689309052
Volume 136
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier E-journals (Freedom Collection)
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 20160531
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: ACRLP
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier ScienceDirect
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1879-2472
  dateEnd: 20160531
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: AIKHN
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1879-2472
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017195
  issn: 0049-3848
  databaseCode: AKRWK
  dateStart: 19720201
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LatwwUIQESi-l6XObJqjQw-7BWcmSbOu4JE22j4QcGshNSLJMHHbtJfYeculH9UP6TRnZ8tJSQkuLMLZkD2NmRtIMmgdC75MszWHXEZFPLxdxTViUMeqi3BrNCbe06KLSzs6T-SX_dCWuttDREAvj3SrD2t-v6d1qHUamgZrTVVn6GF8umc8GL7rjNG-3c556WT_8tnHzoCmVfRUDLiP_9U9RwjeHvhTBEsxa7-IlupSnjD60QT2kgHYb0clT9CRokHjW_-Qu2nLVM_ToLJyRP0frWdWWpvbegbit8XG9BOMf86nA4-Ml3Ca4LvCP73F0urizdZenAd5TPIax0ws6wdAbyqa0GAhfrq7rBq5FuSpzPNYXXybdMOC4w6Hmd_MCXZ58-Ho0j0JxhcjyhLURGFJaFqkm0kIrnCW5s1kurWU8M4VJYxMzLYnOGDwYwwTTJk_TnJgcbMqEvUTbVV251wgXSaJTExeZ5sDf2OhMOEG4yx23GRd0hMRAUWVD5nFfAGOhBhezGzVwQnlOKMIVcGKEphu4VZ97448Q6cAwNUSWwlqoYHv4N0jXhCndKKqaWBH1m9iNkNxA_iK5f4X13SBVCqa1P6vRlavXgC0BRZJIIuIRetWL24YGYLFCy-ib_8C8hx77Xu94_BZtt7drtw_qVWsOuvlzgHZmHz_Pz-8B2kQkeQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQw0KqKBFwQb7a8jMRh95CuHduJc6xa2gV2qx5aqTfLdhyRajdZkeyhl34UH8I3MU6cFQhVIJAVJbEzmmhmbM_I80DofSLTHHYdEfn0chHXhEWSURfl1mhOuKVFF5W2OE1mF_zTpbjcQYdDLIx3qwxrf7-md6t16JkGak7XZeljfHnGfDZ40R2ngd1-h3uJAqHev9n6edCUZn0ZA55F_vOfwoSv9n0tghXYtd7HS3Q5Txm9bYe6TQPtdqLjh-hBUCHxQf-Xj9COqx6ju4twSP4EbQ6qtjS1dw_EbY2P6hVY_5hPBR4freA2wXWBv3-Lo5Plta27RA0wTvEY-k7O6ATD21A3pcVA-XL9pW7gWpbrMsdjfTafdN2A4xqHot_NU3Rx_OH8cBaF6gqR5QlrI7CkdFakmmQWWuEsyZ2VeWYt49IUJo1NzHRGtGTwYAwTTJs8TXNicjAqE_YM7VZ15V4gXCSJTk1cSM2BwbHRUjhBuMsdt5ILOkJioKiyIfW4r4CxVIOP2ZUaOKE8JxThCjgxQtMt3LpPvvFHiHRgmBpCS2ExVLA__Buka8KcbhRVTayI-k3uRijbQv4iun-F9d0gVQrmtT-s0ZWrN4AtAU2SZETEI_S8F7ctDcBkhSbp3n9gfovuzc4XczX_ePr5JbrvR3ov5Fdot_26ca9B12rNm24u_QBVHiYK
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibodies+to+Domain+4%2F5+%28Dm4%2F5%29+of+%CE%B22-Glycoprotein+1+%28%CE%B22GP1%29+in+different+antiphospholipid+%28aPL%29+antibody+profiles&rft.jtitle=Thrombosis+research&rft.au=Pengo%2C+V.&rft.au=Ruffatti%2C+A.&rft.au=Tonello%2C+M.&rft.au=Hoxha%2C+A.&rft.date=2015-07-01&rft.pub=Elsevier+Ltd&rft.issn=0049-3848&rft.eissn=1879-2472&rft.volume=136&rft.issue=1&rft.spage=161&rft.epage=163&rft_id=info:doi/10.1016%2Fj.thromres.2015.04.031&rft.externalDocID=S0049384815002030
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00493848%2FS0049384815X00089%2Fcov150h.gif